DTHC CELEBRATES NEWS THAT LONG-ACTING INJECTABLE PrEP IS EFFECTIVE FOR THE PREVENTION OF HIV INFECTION IN CISGENDER MEN AND TRANSGENDER WOMEN

18 MAY 2020 – The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP). The study showed that CAB LA lowered HIV incidence among cisgender men and…

HVTN702 HIV Vaccine Trial Discontinued

The Desmond Tutu HIV Centre greets with great disappointment the news that the Phase 2b/3 HIV vaccine study HVTN 702 conducted by the HIV Vaccine Trials Network has been stopped by the National Institute of Allergy and Infectious Diseases (NIAID), the trial sponsors. The decision comes after a recommendation from the independent Data and Safety…